Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Recruiting

Phase 1

Pembrolizumab & ChemotherapyPembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT03760575

Conditions

Mesotheliomas Pleural

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Indocyanine Green (ICG) Image-Guided Surgery

Cisplatin

Pemetrexed

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2025-01-24.